SCHEMBL10257500

SCHEMBL10257500

CCOC(=O)C=Cc1cccn2nc(C)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CCNC P24863 5/20 0.42
CDK8 P49336 5/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CYP3A4 P08684 2/20 0.40
TTR P02766 1/20 0.40
DPP4 P27487 1/20 0.40
STAT3 P40763 1/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
MDM2 Q00987 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL544106 1.00 CA12 (0.43) CA12CA1CA2CA7CA9
SCHEMBL2778475 0.84 NFKB1 (0.41) CA1CA2NPC1RAB9AMAPT
SCHEMBL10257389 0.79 TTR (0.45) CA12CA1CA2CA7CA9
SCHEMBL544120 0.79 TTR (0.45) CA12CA1CA2CA7CA9
SCHEMBL10783189 0.75 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL543682 0.74 ALDH1A1 (0.38) NPC1RAB9AMAPTLMNAKDM4E
SCHEMBL11054639 0.74 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL5275455 0.72 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL5275457 0.72 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL31440107 0.72 NPC1 (0.45) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH CA12 2291/4885CA1 2112/4885CA2 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.